Antibody conjugate radioimmunotherapy of superficial bladder cancer
The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Instituto de Tecnologia do Paraná - Tecpar
2002
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1516-89132002000500012 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1516-891320020005000122002-10-18Antibody conjugate radioimmunotherapy of superficial bladder cancerPerkins,AlanHopper,MelanieMurray,AndreaFrier,MalcolmBishop,Mike Antibody radioimmunotherapy bladder cancer The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun.info:eu-repo/semantics/openAccessInstituto de Tecnologia do Paraná - TecparBrazilian Archives of Biology and Technology v.45 n.spe 20022002-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012en10.1590/S1516-89132002000500012 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Perkins,Alan Hopper,Melanie Murray,Andrea Frier,Malcolm Bishop,Mike |
spellingShingle |
Perkins,Alan Hopper,Melanie Murray,Andrea Frier,Malcolm Bishop,Mike Antibody conjugate radioimmunotherapy of superficial bladder cancer |
author_facet |
Perkins,Alan Hopper,Melanie Murray,Andrea Frier,Malcolm Bishop,Mike |
author_sort |
Perkins,Alan |
title |
Antibody conjugate radioimmunotherapy of superficial bladder cancer |
title_short |
Antibody conjugate radioimmunotherapy of superficial bladder cancer |
title_full |
Antibody conjugate radioimmunotherapy of superficial bladder cancer |
title_fullStr |
Antibody conjugate radioimmunotherapy of superficial bladder cancer |
title_full_unstemmed |
Antibody conjugate radioimmunotherapy of superficial bladder cancer |
title_sort |
antibody conjugate radioimmunotherapy of superficial bladder cancer |
description |
The administration of antibody conjugates for cancer therapy is now proving to be of clinical value. We are currently undertaking a programme of clinical studies using the monoclonal antibody C595 (IgG3) which reacts with the MUC1 glycoprotein antigen that is aberrantly expressed in a high proportion of bladder tumours. Radioimmunoconjugates of the C595 antibody have been produced with high radiolabelling efficiency and immunoreactivity using Tc-99m and In-111 for diagnostic imaging, and disease staging and the cytotoxic radionuclides Cu-67 and Re-188 for therapy of superficial bladder cancer. A Phase I/II therapeutic trail involving the intravesical administration of antibody directly into the bladder has now begun. |
publisher |
Instituto de Tecnologia do Paraná - Tecpar |
publishDate |
2002 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-89132002000500012 |
work_keys_str_mv |
AT perkinsalan antibodyconjugateradioimmunotherapyofsuperficialbladdercancer AT hoppermelanie antibodyconjugateradioimmunotherapyofsuperficialbladdercancer AT murrayandrea antibodyconjugateradioimmunotherapyofsuperficialbladdercancer AT friermalcolm antibodyconjugateradioimmunotherapyofsuperficialbladdercancer AT bishopmike antibodyconjugateradioimmunotherapyofsuperficialbladdercancer |
_version_ |
1756423669418033152 |